Literature DB >> 34085800

Relevance of pathologic features in risk stratification for early-stage endometrial cancer.

Esther Guerra1, Xavier Matias-Guiu1,2.   

Abstract

Entities:  

Year:  2021        PMID： 34085800      PMCID： PMC8192231          DOI： 10.3802/jgo.2021.32.e67

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN： 2005-0380            Impact factor:   4.401


× No keyword cloud information.
  9 in total

1.  Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.

Authors:  Sònia Gatius; Dolors Cuevas; Carlos Fernández; Berta Roman-Canal; Virginia Adamoli; Josep Maria Piulats; Núria Eritja; Mireia Martin-Satue; Gema Moreno-Bueno; Xavier Matias-Guiu
Journal:  Pathobiology       Date:  2017-06-15       Impact factor: 4.342

2.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Authors:  Tjalling Bosse; Remi A Nout; Jessica N McAlpine; Melissa K McConechy; Heidi Britton; Yaser R Hussein; Carlene Gonzalez; Raji Ganesan; Jane C Steele; Beth T Harrison; Esther Oliva; August Vidal; Xavier Matias-Guiu; Nadeem R Abu-Rustum; Douglas A Levine; C Blake Gilks; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

3.  Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging.

Authors:  Christine H Kim; Robert A Soslow; Kay J Park; Emma L Barber; Fady Khoury-Collado; Joyce N Barlin; Yukio Sonoda; Martee L Hensley; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2013-06       Impact factor: 3.437

4.  Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens.

Authors:  J Mitchard; L Hirschowitz
Journal:  Histopathology       Date:  2003-04       Impact factor: 5.087

5.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Xavier Matias-Guiu; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio Gonzalez Martin; Sigurd Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina Sturdza; Alexandra Taylor; Anneke Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Carien L Creutzberg
Journal:  Radiother Oncol       Date:  2021-01       Impact factor: 6.280

6.  Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.

Authors:  Manon Daix; Martina Aida Angeles; Federico Migliorelli; Athanasios Kakkos; Carlos Martinez Gomez; Katty Delbecque; Eliane Mery; Stéphanie Tock; Erwan Gabiache; Marjolein Decuypere; Frédéric Goffin; Alejandra Martinez; Gwénaël Ferron; Frédéric Kridelka
Journal:  J Gynecol Oncol       Date:  2021-04-05       Impact factor: 4.401

7.  A clinically applicable molecular-based classification for endometrial cancers.

Authors:  A Talhouk; M K McConechy; S Leung; H H Li-Chang; J S Kwon; N Melnyk; W Yang; J Senz; N Boyd; A N Karnezis; D G Huntsman; C B Gilks; J N McAlpine
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

8.  Integrated genomic characterization of endometrial carcinoma.

Authors:  Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine
Journal:  Nature       Date:  2013-05-02       Impact factor: 49.962

9.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Authors:  Nicoletta Colombo; Carien Creutzberg; Frederic Amant; Tjalling Bosse; Antonio González-Martín; Jonathan Ledermann; Christian Marth; Remi Nout; Denis Querleu; Mansoor Raza Mirza; Cristiana Sessa
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.